Welcome to our dedicated page for AKTIS ONCOLOGY SEC filings (Ticker: AKTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to aggregate U.S. regulatory filings for Aktis Oncology, Inc. (Nasdaq: AKTS), a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors. While specific SEC filings are not listed in the provided information, a Nasdaq-listed issuer such as Aktis Oncology would typically use SEC reports to describe its business, pipeline, risks, and capital structure in more detail.
Annual and quarterly reports, such as Forms 10-K and 10-Q when available, generally provide narrative and financial disclosure about companies like Aktis Oncology. For a clinical-stage radiopharmaceutical company, these documents often include descriptions of its miniprotein radioconjugate platform, targeted tumor types, clinical development plans, and factors that could affect its research and development activities.
Registration statements, such as the Form S-1 that Aktis Oncology reports was declared effective in connection with its initial public offering, offer additional background on the company’s history, founding, and the structure of its capital raising transactions. Aktis Oncology has stated that its common stock began trading on the Nasdaq Global Select Market under the ticker AKTS following the effectiveness of its Form S-1.
On this filings page, Stock Titan’s tools can be used to review such documents when they are available from the SEC’s EDGAR system. AI-powered summaries are designed to highlight key sections of lengthy filings, such as business descriptions, risk factors related to clinical development and radiopharmaceutical safety, and disclosures about collaborations like the company’s strategic relationship with Eli Lilly and Company.
Users interested in AKTS can use this page to monitor new filings as they appear, compare successive disclosures, and better understand how Aktis Oncology presents its radiopharmaceutical platform, pipeline candidates, and single operating segment focused on research and development in official regulatory documents.
Aktis Oncology, Inc. director and 10% owner Kim Helen Susan reported indirect ownership changes tied to the company’s initial public offering. Investment entities Vida Ventures II, LLC and Vida Ventures II-A, LLC converted their Series A and Series B Redeemable Convertible Preferred Stock into Common Stock on a 3.8044-for-1 basis immediately before the IPO closing, with no additional cash paid. Following these conversions and additional purchases at $18 per share on the same date, Vida Ventures II, LLC held 5,671,825 shares of Common Stock and Vida Ventures II-A, LLC held 157,387 shares, over which various Vida Ventures entities and committee members, including the reporting person, may be deemed to share voting and investment power, subject to pecuniary-interest disclaimers.
Aktis Oncology, Inc. director Segal Lloyd Mitchell reported an automatic conversion of preferred stock into common shares tied to the company’s initial public offering. On 01/12/2026, Arvala, Inc., an entity for which Mitchell is president and sole stockholder, converted 50,000 shares of Series A Redeemable Convertible Preferred Stock and 24,687 shares of Series B Redeemable Convertible Preferred Stock into the issuer’s common stock on a 3.8044-for-1 basis without any cash payment. This conversion resulted in 19,631 shares of common stock, all held indirectly through Arvala, Inc., and reflects the automatic conversion that occurred immediately before the closing of the IPO.
Aktis Oncology, Inc. adopted an amended and restated certificate of incorporation and bylaws in connection with the completion of its initial public offering on January 12, 2026. The new charter authorizes 480,000,000 shares of common stock, 10,000,000 shares of Class A common stock, and 10,000,000 shares of undesignated preferred stock that the board may issue in one or more series. It also eliminates prior preferred stock series, requires at least a two-thirds stockholder vote to remove a director for cause, creates a classified board with directors serving staggered three-year terms, and removes stockholder action by written consent.
The amended and restated bylaws, effective immediately prior to the IPO, establish detailed procedures for stockholder proposals and director nominations, revise indemnification provisions for directors and officers, and align the bylaws with the new charter terms.
Aktis Oncology, Inc. Chief Financial Officer Kyle D. Kuvalanka filed an initial Form 3 reporting his beneficial ownership of stock options in the company. He directly holds a stock option to buy 370,423 shares of common stock at an exercise price of $11.46 per share, exercisable until 12/11/2035, and another option to buy 131,426 shares at $18 per share, exercisable until 01/07/2036.
For the first option grant, 25% of the shares will vest on November 3, 2026, with the remainder vesting in equal monthly installments over the following three years, subject to his continued service. For the second grant, 25% of the shares will vest on January 8, 2027, with the balance vesting monthly thereafter on the same continued-service condition. The filing does not show any stock sales or purchases, only these option holdings.
Aktis Oncology director and 10% owner Helen Susan Kim reported her initial beneficial ownership in the company as of January 8, 2026. Most of the reported holdings are indirect interests in Series A and Series B Redeemable Convertible Preferred Stock held by Vida Ventures II, LLC and Vida Ventures II-A, LLC, where investment and voting decisions may be made through affiliated management entities and committees, and each participant only benefits to the extent of their pecuniary interest.
Each share of Series A and Series B preferred stock is convertible into common stock on a 3.8044-for-1 basis and is expected to convert automatically into common shares immediately before the closing of an initial public offering of Aktis Oncology common stock without additional payment. Kim also holds a stock option for 37,866 common shares at $18 per share, with 1/36 of the option vesting monthly starting January 8, 2026, subject to her continued service.
Aktis Oncology director Ken Herrmann filed an initial Form 3 reporting his beneficial ownership in the company mainly through stock options to buy common stock.
The filing lists six stock option grants with exercise prices from $0.08 to $18.00 per share and expiration dates between November 23, 2030 and January 7, 2036. Options covering 6,571 and 19,714 shares have vested in full, while other grants, including 26,285, 64,399 and 10,514 underlying shares, vest in monthly installments tied to his continuous service. A grant covering 18,933 shares is scheduled to vest in full on January 8, 2027. All reported options are held directly.
Aktis Oncology, Inc. reported initial insider holdings by investment entities associated with MPM Bioimpact. The filing shows indirect beneficial ownership of 341,709 shares of Common Stock and indirect holdings of preferred stock that can convert into Common Stock. These include 1,314,262 shares of Series Seed Redeemable Convertible Preferred Stock, 5,914,197 shares of Series A Redeemable Convertible Preferred Stock, and 1,577,119 shares of Series B Redeemable Convertible Preferred Stock, all held indirectly through funds and entities such as MPM Asset Management LLC and various MPM BioVentures and Oncology funds.
Each share of the Series Seed, Series A and Series B preferred stock is convertible into Common Stock on a 3.8044-for-1 basis, and these preferred shares will convert into Common Stock upon the closing of the company’s initial public offering. The reporting persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Aktis Oncology director Lloyd Mitchell Segal filed an initial Form 3 reporting his equity interests as of January 8, 2026. Indirect holdings include 13,142 shares of Series A Redeemable Convertible Preferred Stock and 6,489 shares of Series B Redeemable Convertible Preferred Stock held by Arvala, Inc., where he is president and sole stockholder and may share voting and dispositive power. Each preferred share is convertible into common stock on a 3.8044-for-1 basis and will automatically convert to common stock immediately before the closing of Aktis Oncology’s initial public offering. He also reports several stock options for common stock, including grants covering 32,856, 31,542, 6,571, 10,514 and 18,933 shares at exercise prices ranging from $1.45 to $18.00, with one grant fully vested and others vesting monthly or in full on January 8, 2027 subject to continued service.
Aktis Oncology, Inc. (AKTS) filed an initial insider ownership report for President and CEO, and director, Matthew Roden as of January 8, 2026. He directly beneficially owns 91,998 shares of common stock and holds several stock option awards. These include options to purchase 578,277 shares at $1.91 per share that have fully vested, as well as options for 558,095 shares at $3.66, 618,757 shares at $9.33, and 394,280 shares at $18 per share, which vest over time according to specified schedules tied to his continued service with the company.
Aktis Oncology, Inc. had several MPM-affiliated investment vehicles file an initial Form 3 to report their beneficial ownership as of 01/08/2026. The group reports indirect ownership of 341,709 shares of common stock and indirect holdings of Series Seed, Series A and Series B Redeemable Convertible Preferred Stock, which are each convertible into common stock on a 3.8044-for-1 basis. The preferred shares will convert into common stock upon the closing of Aktis Oncology’s initial public offering and have no expiration date. The reporting persons state that they disclaim beneficial ownership of these securities except to the extent of their pecuniary interest, and the shares are held through various MPM-managed funds and entities.